The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.

Background: Chloroquine/primaquine is the current therapy to eliminate Plasmodium vivax infection in the Amazon region.

Aims: This study investigates CYP1A2, CYP2C8, CYP2C9, CYP3A4 and CYP3A5 genetic polymorphisms influence on cloroquine/primaquine treatment.

Patients & Methods: Generalized estimating equations analyses were performed to determine the genetic influence in parasitemia and/or gametocytemia clearance over treatment time in 164 patients.